Showing results (191-200 of 279) with videos related to

Sort By:
Pageof 28
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 28, 2024
Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [68Ga]Ga-ABY-025: Results from a Pilot StudyRenske Altena, Siri Af Burén, August Blomgren, et al.
Acta Oncologica (Stockholm, Sweden)|April 30, 2020
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1Paula Poikonen-Saksela, Henrik Lindman, Asgerdur Sverrisdottir, et al.
ESMO Open|September 27, 2019
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapyKyriaki Tzogani, Beatriz Florez, Greg Markey, et al.
Scientific Reports|December 20, 2019
CETSA-based target engagement of taxanes as biomarkers for efficacy and resistanceAnette Langebäck, Smaranda Bacanu, Henriette Laursen, et al.
Breast Cancer Research and Treatment|July 4, 2021
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei-Yin C Polley, Maura N Dickler, Jason Sinnwell, et al.
Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.
Cell|July 11, 2008
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expressionSamuel Godar, Tan A Ince, George W Bell, et al.
Medical Oncology (Northwood, London, England)|December 17, 2002
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trialAke Berglund, Bengt Glimelius, Jonas Bergh, et al.
Genome Biology|April 27, 2013
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosisSrikanth Nagalla, Jeff W Chou, Mark C Willingham, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Pageof 28